What evidence supports and refutes the effectiveness of the seasonal influenza vaccine?

Flu Shot Effectiveness: Evidence Summary

Annual influenza vaccination is moderately effective and strongly recommended for all persons aged ≥6 months without contraindications, preventing an estimated 1.6-6.7 million illnesses, 39,000-87,000 hospitalizations, and 3,000-10,000 deaths each season in the United States. 1, 2

Evidence Supporting Effectiveness

Overall Protection Rates

The most recent comprehensive guidelines from ACIP consistently demonstrate that seasonal influenza vaccination provides meaningful protection across multiple outcomes 1, 2, 3:

• Against any influenza illness: 38-45% effectiveness in recent seasons 1, 4
• Against hospitalization: 41-42% effectiveness overall 5, 6
• Against death: 36% effectiveness 5
• Against ICU admission: 52% effectiveness 5
• Against need for ventilatory support: 55% effectiveness 5

During the severe 2017-18 season, despite overall vaccine effectiveness of only 38%, vaccination still prevented 7.1 million illnesses, 3.7 million medical visits, 109,000 hospitalizations, and 8,000 deaths 1, 2. This demonstrates that even modest effectiveness translates to substantial public health benefit when applied at population scale.

Strain-Specific Effectiveness

Vaccine performance varies significantly by circulating virus type 1, 2, 4:

• Influenza A(H1N1)pdm09: 37-62% effectiveness
• Influenza A(H3N2): 22-37% effectiveness (consistently lower)
• Influenza B: 50-51% effectiveness

The lower effectiveness against H3N2 is particularly notable and represents a consistent pattern across multiple seasons 2, 6.

Age-Specific Protection

Children demonstrate substantially higher vaccine effectiveness - up to 2-fold greater than adults 5:

• Children aged 6 months-17 years: 55% effectiveness 4
• Adults aged 18-64 years: 51% effectiveness 5
• Adults aged ≥65 years: 37% effectiveness 5, 6

The pediatric benefit is especially pronounced with live attenuated vaccines, showing 83% efficacy in children aged 6 months to 7 years 7.

Special Populations

For patients with cardiovascular disease, influenza vaccination provides critical protection. A randomized controlled trial (FLUVACS) demonstrated that vaccinated patients hospitalized for acute coronary syndromes had a relative risk of cardiovascular mortality of 0.25 (95% CI 0.07-0.86) at one year compared to unvaccinated patients - a 75% reduction 8.

Evidence Against or Limiting Effectiveness

Waning Immunity

Multiple observational studies document declining protection within a single season 9, 2, 9:

• Vaccine effectiveness decreases approximately 7% per month for H3N2 and influenza B
• Decreases 6-11% per month for H1N1pdm09 2
• Among adults ≥65 years, decline is more pronounced at 8-11% per month 2
• Effectiveness remains greater than zero for at least 5-6 months post-vaccination 9, 2

One European analysis found VE against H3N2 declined to 0% at 111 days post-vaccination, though protection against H1N1pdm09 remained stable at 50-55% throughout the season 2.

Common pitfall: This waning effect creates tension between vaccinating early (July-August) and maintaining protection through late-season peaks. The guidelines are clear: vaccination in July-August is NOT recommended for most groups due to waning concerns 2, 3. Optimal timing is September-October, though vaccination should continue throughout the season 1, 2.

Vaccine-Strain Mismatch

Effectiveness is substantially reduced when circulating viruses differ antigenically from vaccine strains:

• In well-matched seasons: 43% effectiveness against H3N2 in elderly 6
• In mismatched seasons with variant H3N2: only 14% effectiveness 6

This represents a fundamental limitation of current vaccine technology, as the vaccine composition must be determined months before the influenza season begins 10.

Repeated Vaccination Concerns

One household study found unexpected lower effectiveness among subjects vaccinated in both current and prior seasons, with significant protection (62%) only in those vaccinated in the current season without prior-season vaccination 11. However, this finding has not been consistently replicated and contradicts the universal annual vaccination recommendation that remains in place 1, 2, 3.

Limited Protection Against Household Transmission

The same household study found no evidence that vaccination prevented household transmission once influenza was introduced, with adults at particular risk despite vaccination 11. This suggests vaccination is more effective at preventing community-acquired infection than blocking transmission in close-contact settings.

Variable Effectiveness in Real-World Settings

A meta-analysis of test-negative design studies found pooled VE of only 27.22% (95% CI: 17.36-37.08%) with significant heterogeneity (I² = 93.2%) 12. This lower estimate reflects real-world conditions including timing misalignment, age distribution, and strain matching issues.

Clinical Algorithm for Decision-Making

All patients ≥6 months should receive annual influenza vaccination unless contraindicated 1, 2, 3. The evidence supporting this recommendation is strongest for:

1. Priority groups (vaccinate first if supply limited) 9:

   • Children 6-59 months
   • Adults ≥50 years (preferably ≥65 years with high-dose or adjuvanted vaccines)
   • Pregnant women (any trimester)
   • Persons with chronic medical conditions (cardiovascular, pulmonary, renal, hepatic, neurologic, hematologic, metabolic disorders)
   • Immunocompromised patients
   • Healthcare personnel
   • Residents of long-term care facilities

2. Timing strategy:

   • Begin vaccination in September-October 1, 2
   • Children requiring 2 doses: start in July-August to complete both doses by October 2
   • Continue vaccination throughout the season, even after influenza activity begins 9
   • Do NOT vaccinate in July-August for single-dose recipients due to waning 2, 3

3. Vaccine selection for adults ≥65 years: Preferentially use high-dose, adjuvanted, or recombinant vaccines over standard-dose 2, 3

Key Caveats

• Even "low" effectiveness of 22% against H3N2 prevents substantial morbidity and mortality at population scale 1
• Vaccine effectiveness estimates vary widely by study design, with test-negative designs generally showing lower estimates than randomized trials 7, 12
• Protection against severe outcomes (hospitalization, death, ICU admission) is consistently higher than protection against any influenza illness 5
• The unpredictable timing of influenza seasons (peak activity in 76% of seasons occurs January or later) supports continued vaccination efforts throughout the season 2

The evidence overwhelmingly supports annual influenza vaccination despite moderate and variable effectiveness, as the benefits in preventing severe disease, hospitalization, and death substantially outweigh the minimal risks 1, 2, 5.